DeğerQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSatış/genel/idari giderler6.45 B6.03 B5.89 B5.92 B6.75 B24.6 BAraştırma ve geliştirme5.3 B3.53 B3.52 B3.67 B4.25 B14.97 BFaaliyet karı-1.14 B5.13 B5.14 B5.95 B677 M16.9 BFaaliyet Dışı Gelir, Toplam442 M-65 M153 M705 M-246 M547 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)137 M272 M308 M245 M214 M1.04 BFaaliyet Dışı Gelir (Faiz Giderleri Hariç)144 M-43 M-48 M-18 M23 M-86 MOlağandışı gelirler/giderler161 M-294 M-107 M478 M-483 M-406 MVergi öncesi kar3.89 B5.99 B6.49 B7.49 B4.97 B24.94 BKazançlardaki özsermayeler——————Vergiler456 M755 M954 M2.34 B-150 M3.9 BKontrol gücü olmayan/azınlık payı——————Vergi sonrası diğer gelirler/giderler——————Durdurulan faaliyetler öncesi net kar3.43 B5.24 B5.54 B5.15 B5.12 B21.04 BDurdurulan faaliyetler0———0—Net kar3.43 B5.24 B5.54 B5.15 B5.12 B21.04 BSeyreltme ayarlaması——————İmtiyazlı temettüler——————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar3.43 B5.24 B5.54 B5.15 B5.12 B21.04 BTemel hisse başına kazanç (Temel EPS)1.422.172.32.142.128.73Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)1.412.142.292.122.088.63Dolaşımdaki ortalama adi hisse senedi sayısı2.41 B2.41 B2.41 B2.41 B2.41 B—Dolaşımdaki seyreltilmiş hisse senedi sayısı2.43 B2.45 B2.42 B2.43 B2.43 B—FAVÖK777 M7.12 B5.97 B5.23 B2.7 B21.03 BFVÖK-1.14 B5.13 B5.14 B5.95 B677 M16.9 BGelir maliyeti7.13 B8.11 B7.63 B7.3 B7.97 B31 BSatılan malların diğer maliyeti——————Amortisman ve itfa (nakit akışı)1.9 B2 B1.94 B1.78 B2.01 B7.74 B
Johnson & Johnson Common Stock
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey.
The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments.
The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.